Assessment of residual risk
in patients at target non high-density lipoprotein cholesterol (HDL-C)
(or low-density lipoprotein-cholesterol: LDL-C);
Follow-up studies in individuals with non-HDL-C (or LDL-C)
values inconsistent with risk factors or clinical presentation; Definitive studies of cardiac
risk factors in individuals with
significant family histories
of coronary artery disease or other increased risk factors; Confirmation of
suspected abetalipoproteinemia or hypobetalipoproteinemia
Centrifuge and aliquot 1 ml of plasma. Send refrigerated.
<24 months: not established
Acceptable: <90 mg/dl
Borderline high: 90-109 mg/dl
High: >=110 mg/dl
Desirable: <90 mg/dl Above Desirable: 90-99 mg/dl Borderline high: 100-119 mg/dl
High: 120-139 mg/dl
Very high: >=140 mg/dl
Elevated ApoB confers increased risk of coronary artery disease ApoB can be used as a therapeutic target analogous to non-HDL-C and LDL-C.
Therapeutic Target: ApoB Non-HDL-C LDL-C
Moderate to High: < 90 mg/dl <130 mg/dl <100 mg/dl
Very High: <80 mg/dl <100 mg/dl <70 mg/dl
Extremely low values of ApoB (<48 mg/dl) are related to malabsorption of food lipids and can lead to polyneuropathy.